Menu

1 / 34

Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market - Pfizer (NYSE:PFE)

Top Stories Feed·Vandana Singh·3 days ago
#Ba6gHTJK
#benzinga#premarin#canada#pfizer#menopause
Reading 0:00
15s threshold

November 13, 2026 10:02 AM 2 min read

Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market

by Vandana Singh Benzinga Staff Writer

Follow

PFEPfizer Inc

$28.77-0.19%

Stock Score Locked: Want to See it?

Benzinga Edge Rankings give you vital metrics on any stock – anytime.

Reveal Full Score Edge Rankings

Momentum78.19

Growth2.12

Quality23.36

Value26.99

Price Trend

ShortMediumLongOverview Pfizer Inc. (NYSE:PFE) will reportedly no longer sell its hormone replacement therapy Premarin in Canada following an internal review, ending Canadian availability of both its vaginal cream and three oral tablet strengths.

Pfizer Canada confirmed to Reuters on Thursday that it will supply no further batches of Premarin vaginal cream, which treats menopause symptoms and has experienced shortages in Canada since June.

Menopause Drug Shortages Strain Canadian Supply

The discontinuation of Premarin products, alongside shortages of certain estradiol patches, could add pressure on Canada’s menopause…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.